In CCA, K50 acetylation (K50ac) of 14-3-3ε leads to activation of YAP1, and the results revealed that 14-3-3ε binds to phosphorylated serine/threonine motifs and may serve as a target for CCA therapy [59]. This evidence concerns the gene YAP1 and cholangiocarcinoma.